`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`MYLAN PHARMACEUTICALS INC., ACTAVIS
`LABORATORIES FL, INC., AMNEAL PHARMACEUTICALS LLC,
`AMNEAL PHARMACEUTICALS OF NEW YORK, LLC, DR. REDDY’S
`LABORATORIES, INC., DR. REDDY’S LABORATORIES, LTD.,
`SUN PHARMACEUTICALS INDUSTRIES, LTD.,
`SUN PHARMACEUTICALS INDUSTRIES, INC.,
`TEVA PHARMACEUTICALS USA, INC., WEST-WARD
`PHARMACEUTICAL CORP., and HIKMA PHARMACEUTICALS, LLC,
`
`Petitioners
`
`v.
`
`JANSSEN ONCOLOGY, INC.,
`
`Patent Owner
`
`Case IPR2016-013321
`Patent 8,822,438 B2
`
`
`
`
`
`DECLARATION OF IVAN T. HOFMANN, CPA/CFF, CLP
`
`
`
`
`1 Case IPR2017-00853 has been joined with this proceeding.
`
`MYLAN PHARMS. INC. EXHIBIT 1151 PAGE 1
`
`
`
`1.
`
`I, Ivan T. Hofmann, am over the age of eighteen (18) and otherwise
`
`competent to make this Declaration. I have personal knowledge of the facts set
`
`forth in this Declaration and am competent to testify to the same.
`
`2.
`
`I have been retained by counsel for Petitioners in connection with the
`
`above-captioned inter partes review (“IPR”).
`
`3.
`
`I am educated and experienced in economics, as detailed in my
`
`Declarations that were filed with the Petition and Reply as Exhibits MYL 1017 and
`
`MYL 1134, and my Curriculum Vitae filed as Attachment A-2 to MYL 1017 and
`
`MYL 1134. I understand that my declaration will be included in Petitioners’
`
`Exhibit List as MYL Ex. 1151. I have examined Exhibit 1141. This exhibit is
`
`publicly available.
`
`4.
`
`Exhibit MYL 1141 is a true and correct copy of a Johnson & Johnson
`
`press release entitled, “Zytiga® Approved In The EU For Use In The Treatment Of
`
`Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy,” dated
`
`January 11, 2013, accessible at https://www.jnj.com/media-center/press-
`
`releases/zytiga-approved-in-the-eu-for-use-in-the-treatment-of-metastatic-
`
`castration-resistant-prostate-cancer-before-chemotherapy.
`
` This Exhibit was
`
`downloaded at my direction and under my supervision. An exhibit label was
`
`added to this exhibit and no other alterations were made.
`
`
`
`
`
`MYLAN PHARMS. INC. EXHIBIT 1151 PAGE 2
`
`
`
`May 10, 2017
`
`Respectfully submitted,
`
`Ivan T. Hofmann, CPA/CFF, CLP
`
`MYLAN PHARMS. INC. EXHIBIT 1151 PAGE 3
`
`